Evidence map›Paper›PMID 24236054›Full record

ArticlePloS one2013

Development of methods for cross-sectional HIV incidence estimation in a large, community randomized trial.

Oliver Laeyendecker, Michal Kulich, Deborah Donnell, Arnošt Komárek, Marek Omelka, Caroline E Mullis, Greg Szekeres, Estelle Piwowar-Manning, Agnes Fiamma, Ronald H Gray and 14 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 14 institutions in 5 countries.

Oliver LaeyendeckerNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America ; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Michal Kulich
Deborah Donnell
Arnošt Komárek
Marek Omelka
Caroline E Mullis
Greg Szekeres
Estelle Piwowar-Manning
Agnes Fiamma
Ronald H Gray
Tom Lutalo
Charles S Morrison
Robert A Salata
Tsungai Chipato
Connie Celum
Erin M Kahle
Taha E Taha
Newton I Kumwenda
Quarraisha Abdool Karim
Vivek Naranbhai
Jairam R Lingappa
Michael D Sweat
Thomas Coates
Susan H Eshleman
Johns Hopkins University · USCharles University · CZUniversity of Washington · USRakai Health Sciences Program · UGUCLA Health · USUniversity of KwaZulu-Natal · ZAFamily Health International 360 · USFred Hutch Cancer Center · USJohns Hopkins Medicine · USMedical University of South Carolina · USNational Institute of Allergy and Infectious Diseases · USUniversity Hospitals Case Medical Center · USUniversity of California, Los Angeles · USUniversity of Zimbabwe · ZW

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI MYRON Scott COHEN, Sinead Delany-Moretlwe · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
HIV PREVENTION TRIALS NETWORK LEADERSHIP GROUPU01AI046749 · NIAID · FAMILY HEALTH INTERNATIONAL · PI CATES, WILLARD · 1999 to 2005
$73.5M
HIV Prevention trials Network (HPTN) Coordinating and Operations CenterU01AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI VERMUND, STEN H. · 2006 to 2010
$72.7M
Leadership for HIV/AIDS Clinical Trials Networks; HIV Prevention Trials NetworkU01AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DONNELL, DEBORAH J · 2006 to 2010
$28.8M
Community-Based HIV VCT: South AfricaU01MH066701 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI COATES, THOMAS J. · 2003 to 2010
$24.3M
TUBERCULOSIS INTERNATIONAL TRAINING AND RESEARCH PROGRAMD43TW000010 · FIC · JOHNS HOPKINS UNIVERSITY · PI BEYRER, CHRISTOPHER C. · 1988 to 2012
$19.8M
HIV Prevention Trials Network: Network LaboratoryU01AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ESHLEMAN, SUSAN H · 2006 to 2010
$16.5M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
Acyclovir to Prevent HIV Acquisition in HSV-2+ PersonsU01AI052054 · NIAID · UNIVERSITY OF WASHINGTON · PI CELUM, CONNIE L · 2005 to 2007
$13.6M
Community-Based VCT: ZimbabweU01MH066702 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MORIN, STEPHEN F · 2003 to 2010
$13.4M
CDC HHS U50/CC0222061FIC NIH HHS 5D43TW00010FIC NIH HHS D43 TW000010NCHHSTP CDC HHS U50 PS022061NCHHSTP CDC HHS U50 PS022061-05NIAID NIH HHS K08 AI0744248NIAID NIH HHS K22 AI092150NIAID NIH HHS K22 AI092150-01NIAID NIH HHS R01 AI095068NIAID NIH HHS R01-AI095068NIAID NIH HHS U01 AI046749NIAID NIH HHS U01 AI052054NIAID NIH HHS U01 AI068613NIAID NIH HHS U01AI068613/UM1AI068613NIAID NIH HHS U01 AI068617NIAID NIH HHS U01AI068617/UM1AI068617NIAID NIH HHS U01 AI068619NIAID NIH HHS U01AI068619/UM1AI068619NIAID NIH HHS U01 AI46749NIAID NIH HHS U01 AI52054NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619NICHD NIH HHS N01-HD-0-3310NICHD NIH HHS R01 HD 050180NICHD NIH HHS R01 HD050180NIMH NIH HHS U01 MH066687NIMH NIH HHS U01MH066687NIMH NIH HHS U01 MH066688NIMH NIH HHS U01MH066688NIMH NIH HHS U01 MH066701NIMH NIH HHS U01MH066701NIMH NIH HHS U01 MH066702NIMH NIH HHS U01MH066702PHS HHS P30 A127757PHS HHS R01 A134265PHS HHS R01 A134826
6 · The paper itself

Abstract

backgroundAccurate methods of HIV incidence determination are critically needed to monitor the epidemic and determine the population level impact of prevention trials. One such trial, Project Accept, a Phase III, community-randomized trial, evaluated the impact of enhanced, community-based voluntary counseling and testing on population-level HIV incidence. The primary endpoint of the trial was based on a single, cross-sectional, post-intervention HIV incidence assessment. METHODS AND

findingsTest performance of HIV incidence determination was evaluated for 403 multi-assay algorithms [MAAs] that included the BED capture immunoassay [BED-CEIA] alone, an avidity assay alone, and combinations of these assays at different cutoff values with and without CD4 and viral load testing on samples from seven African cohorts (5,325 samples from 3,436 individuals with known duration of HIV infection [1 month to >10 years]). The mean window period (average time individuals appear positive for a given algorithm) and performance in estimating an incidence estimate (in terms of bias and variance) of these MAAs were evaluated in three simulated epidemic scenarios (stable, emerging and waning). The power of different test methods to detect a 35% reduction in incidence in the matched communities of Project Accept was also assessed. A MAA was identified that included BED-CEIA, the avidity assay, CD4 cell count, and viral load that had a window period of 259 days, accurately estimated HIV incidence in all three epidemic settings and provided sufficient power to detect an intervention effect in Project Accept.

conclusionsIn a Southern African setting, HIV incidence estimates and intervention effects can be accurately estimated from cross-sectional surveys using a MAA. The improved accuracy in cross-sectional incidence testing that a MAA provides is a powerful tool for HIV surveillance and program evaluation.

Indexed as

AfricaAlgorithmsCross-Sectional StudiesEpidemicsFemaleHIV InfectionsHumansIncidenceMaleRandomized Controlled Trials as Topic

Identifiers

PMID24236054
PMCPMC3827276
OpenAlexW2051130064

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.